Current data from 2025/2026 show: 1.54 billion adults worldwide are affected – and the risk of serious cardiovascular events increases in proportion to the number of components. New evidence on pathophysiology, heart failure risk and treatability. Metabolic syndrome (MetS) is the fastest growing cardiometabolic risk entity worldwide. A global modeling study published in Nature Communications in December 2025 with data from over 45 million adults puts the total prevalence at 1.54 billion people – a doubling within two decades. With increasing component load, the risk of MACE, heart failure incidence and overall mortality increase in a clinically highly relevant dose-response relationship. At the same time, new trials provide evidence for the first time that the MetS can be sustainably remitted with targeted intervention.
Jetzt beitreten
